Xanthi Coskinas

1.8k total citations
16 papers, 59 citations indexed

About

Xanthi Coskinas is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Xanthi Coskinas has authored 16 papers receiving a total of 59 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 6 papers in Cancer Research and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Xanthi Coskinas's work include Prostate Cancer Treatment and Research (7 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Cancer Genomics and Diagnostics (5 papers). Xanthi Coskinas is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Prostate Cancer Diagnosis and Treatment (5 papers) and Cancer Genomics and Diagnostics (5 papers). Xanthi Coskinas collaborates with scholars based in Australia, United Kingdom and United States. Xanthi Coskinas's co-authors include Andrew Martin, Martin R. Stockler, John Simes, R. John Simes, Ian D. Davis, Ray McDermott, Nicola Jane Lawrence, Paul L. Nguyen, Leonie S. Young and Wendy Hague and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Breast Cancer Research and Treatment.

In The Last Decade

Xanthi Coskinas

16 papers receiving 59 citations

Peers

Countries citing papers authored by Xanthi Coskinas

Since Specialization

Citations

This map shows the geographic impact of Xanthi Coskinas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xanthi Coskinas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xanthi Coskinas more than expected).

Fields of papers citing papers by Xanthi Coskinas

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xanthi Coskinas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xanthi Coskinas. The network helps show where Xanthi Coskinas may publish in the future.

Co-authorship network of co-authors of Xanthi Coskinas

This figure shows the co-authorship network connecting the top 25 collaborators of Xanthi Coskinas. A scholar is included among the top collaborators of Xanthi Coskinas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xanthi Coskinas. Xanthi Coskinas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Changes to design and analysis elements of research plans during randomised controlled trials in Australia 2022 ·The Medical Journal of Australia ·Xanthi Coskinas, R. John Simes, Andrew Martin	2
2	Reacting to prognostic covariate imbalance in randomised controlled trials 2021 ·Contemporary Clinical Trials ·Xanthi Coskinas, (unknown), John Simes, Andrew Martin	3
3	Changes to aspects of ongoing randomised controlled trials with fixed designs 2020 ·Trials ·Xanthi Coskinas, John Simes, (unknown), Andrew Martin	4
4	What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators’ Preferences in the SORCE Trial 2018 ·PubMed ·Nicola Jane Lawrence, Andrew Martin, Ian D. Davis, (unknown), Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, (unknown), A.W.S. Ritchie, Angela Meade, Tim Eisen, Prunella Blinman, Martin R. Stockler	4
5	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for high risk, clinically localized prostate cancer: ENZARAD (ANZUP 1303). 2018 ·Journal of Clinical Oncology ·Scott Williams, Ian D. Davis, Christopher J. Sweeney, Martin R. Stockler, Andrew Martin, Wendy Hague, Xanthi Coskinas, Sonia Yip, Emily Tu, Nicola Jane Lawrence, (unknown), Ray McDermott, Paul Kelly, (unknown), Simon Hughes, Valérie Fonteyne, Bertrand Tombal, Paul L. Nguyen	5
6	Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? 2017 ·Annals of Oncology ·Prunella Blinman, (unknown), Andrew Martin, (unknown), Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, A.W.S. Ritchie, Angela Meade, Tim Eisen, Martin R. Stockler	12
7	Predicted benefits of adjuvant sorafenib after nephrectomy for renal cell carcinoma (RCC) in SORCE: an international, placebo-controlled, randomised phase 3 trial 2017 ·Annals of Oncology ·Nicola Jane Lawrence, Amelia Rodríguez Martín, Ian D. Davis, (unknown), Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Raphael Kaplan, (unknown), Angela Meade, (unknown), Prunella Blinman, Martin R. Stockler	1
8	Randomised phase III trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised, high risk, or node-positive prostate cancer: ENZARAD (ANZUP 1303). 2017 ·Journal of Clinical Oncology ·Scott Williams, Ian D. Davis, Christopher Sweeney, Martin R. Stockler, Andrew Martin, Wendy Hague, Xanthi Coskinas, Sonia Yip, Emily Tu, Nicola Jane Lawrence, Ray McDermott, Paul Kelly, (unknown), Simon Hughes, Valérie Fonteyne, Bertrand Tombal, Paul L. Nguyen, (unknown)	1
9	Randomised phase 3 trial of enzalutamide in first-line androgen deprivation therapy for metastatic prostate cancer: The ANZUP ENZAMET Trial (ANZUP 1304). 2016 ·Journal of Clinical Oncology ·Ian D. Davis, Martin R. Stockler, Andrew Martin, Wendy Hague, Xanthi Coskinas, Sonia Yip, Emily Tu, Nicola Jane Lawrence, (unknown), Ray McDermott, Simon Chowdhury, (unknown), (unknown), Francisco Vera-Badillo, Scott North, (unknown), Christopher J. Sweeney, (unknown)	2
10	Oncologists' estimates of expected survival time and scenarios for survival: accuracy in the ALTG NITRO trial of 1st line chemotherapy for advanced non–small-cell lung cancer. 2016 ·Journal of Clinical Oncology ·Annette Tognela, David Espinoza, Andrew R. Davidson, Matthew Chan, Brett Hughes, Michael Boyer, Karen Briscoe, Stephen Begbie, (unknown), Xanthi Coskinas, Nick Pavlakis, Michael Millward, Martin R. Stockler, Belinda E. Kiely, (unknown)	2
11	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy (ADT) with radiation therapy for clinically localised high-risk or node-positive prostate cancer: ENZARAD (ANZUP 1303). 2016 ·Journal of Clinical Oncology ·Scott Williams, Ian D. Davis, Christopher J. Sweeney, Martin R. Stockler, Andrew Martin, Wendy Hague, Xanthi Coskinas, Sonia Yip, Emily Tu, (unknown), Nicola Jane Lawrence, Ray McDermott, Simon Hughes, (unknown), (unknown), Paul L. Nguyen, (unknown)	1
12	Patients' preferences for adjuvant sorafenib after resection of intermediate or high-risk renal cell carcinoma in the SORCE trial: What makes it worthwhile? 2015 ·Journal of Clinical Oncology ·Prunella Blinman, Ian D. Davis, Andrew Martin, (unknown), Shomik Sengupta, Elizabeth Hovey, Xanthi Coskinas, Richard Kaplan, A.W.S. Ritchie, Angela Meade, Tim Eisen, Martin R. Stockler	1
13	Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised prostate cancer: The ANZUP ENZARAD Trial (ANZUP 1303). 2015 ·Journal of Clinical Oncology ·Scott Williams, Ian D. Davis, Christopher J. Sweeney, Martin R. Stockler, Andrew Martin, (unknown), (unknown), Ray McDermott, A. Long, Felicia Roncolato, Sonia Yip, Wendy Hague, Emily Tu, Xanthi Coskinas, Paul L. Nguyen	2
14	Randomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: Enzamet (Anzup 1304) 2014 ·Annals of Oncology ·Ian D. Davis, Martin R. Stockler, Andrew Martin, A. Long, Sonia Yip, Xanthi Coskinas, Christopher J. Sweeney	2
15	Randomised Phase 3 Trial of Enzalutamide in Androgen Deprivation Therapy with Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer: Enzarad (Anzup 1303) 2014 ·Annals of Oncology ·Scott Williams, Ian D. Davis, Christopher J. Sweeney, Martin R. Stockler, Andrew Martin, A. Long, Sonia Yip, Xanthi Coskinas, Paul L. Nguyen	1
16	Comparing patients’ and clinicians’ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial) 2008 ·Breast Cancer Research and Treatment ·(unknown), P. Grantley Gill, Neil Wetzig, T. Sourjina, Val Gebski, Owen Ung, Ian Campbell, James Kollias, Xanthi Coskinas, (unknown), Leonie S. Young, R. John Simes, Martin R. Stockler	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact